Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 AlteredExpression disease BEFREE The present study aimed to examine whether CCN1 can activate HSCs and affect the function of activated HSCs in promoting the progression of HCC. 29286082 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 Biomarker disease BEFREE Our findings indicate that ATF3 functions as a tumor suppressor in HCC through targeting and regulating CYR61. 30376856 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 AlteredExpression disease BEFREE By analyzing the data of GEO Database, we found that Oxa aberrantly increased the expression of Cysteine-rich61 (Cyr61) in HCC cell lines. 30410600 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 Biomarker disease BEFREE Consequently, Ccn1(dm/dm) mice exhibit diminished p53 activation and elevated compensatory hepatocyte proliferation, resulting in increased HCC. 26028023 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 AlteredExpression disease BEFREE Furthermore, we found that over-expression of Cyr61 in HepG2 cells promoted the progression of HCC xenografts in SCID mice. 22540002 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 AlteredExpression disease BEFREE Cyr61 expression was down-regulated in HCC tumors as measured by quantitative real-time PCR and its protein level was decreased in most HCC cell lines as detected by Western blot. 17698398 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 Biomarker disease CTD_human Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. 17699798 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 AlteredExpression disease LHGDN An examination of the d(CA) dinucleotide patterns in the Cyr61 promoter in HCC patients revealed that approximately 32% of these patients exhibited either loss of heterozygosity or somatic mosaicism in either the tumors, adjacent normal liver tissues or both. 15782120 2005
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 GeneticVariation disease BEFREE An examination of the d(CA) dinucleotide patterns in the Cyr61 promoter in HCC patients revealed that approximately 32% of these patients exhibited either loss of heterozygosity or somatic mosaicism in either the tumors, adjacent normal liver tissues or both. 15782120 2005
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 Biomarker disease LHGDN The expressions of Cyr61 and CTGF mRNA in HCC with venous invasion were higher than those in HCC without venous invasion. 15526358 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.380 AlteredExpression disease BEFREE The expressions of Cyr61 and CTGF mRNA in HCC with venous invasion were higher than those in HCC without venous invasion. 15526358 2004